SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
September 25, 2001
Date of Report
BRISTOL-MYERS SQUIBB COMPANY
 (Exact name of registrant as specified in its charter)
Delaware
 (State or other jurisdiction of incorporation)

                1-1136                                    22-079-0350
       (Commission File Number)             (IRS Employer Identification Number)

     345 Park Avenue, New York, NY                           10154

(Address of principal executive offices)                   (Zip Code)	

(212) 546-4000

Item 5. OTHER EVENTS
Incorporated by reference in its entirety is a press release issued by the registrant on September 25, 2001, attached as exhibit 99.1, concerning the registrant's announcement that it expects to re-file its New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for VANLEV(R).
Item 7. FINANCIAL STATEMENTS AND EXHIBITS
(a) Financial Statements
Inapplicable.
(b) Pro Forma Financial Information
Inapplicable.
(c) Exhibit.
99.1 Press Release dated September 25, 2001.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BRISTOL-MYERS SQUIBB COMPANY

By: /s/  Sandra Leung
    -------------------------------
    Name:  Sandra Leung
    Title: Corporate Secretary	

EXHIBIT INDEX

Exhibit No.           Description of the Exhibit
-----------           --------------------------
99.1                  Press Release dated  September 25, 2001	

Exhibit 99.1
Contact: MEDIA: INVESTOR: BRISTOL-MYERS SQUIBB BRISTOL-MYERS SQUIBB
Peggy Ballman                               Timothy Cost
(609) 252-3366                              (212) 546-4103
margaret.ballman@bms.com                    timothy.cost@bms.com
------------------------	

BRISTOL-MYERS SQUIBB TO RE-FILE VANLEV NDA
(NEW YORK, September 25, 2001) - Bristol-Myers Squibb Company (NYSE:BMY) announced today that it expects to re-file its New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for VANLEV (R), its novel medicine for the treatment of hypertension.
Peter R. Dolan, chairman and chief executive officer of Bristol-Myers Squibb, said, "We are pleased to announce that after review and analysis of the results of our landmark 25,000 patient OCTAVE* study of VANLEV, we expect to make our submission for the use of VANLEV in hypertension to the FDA by the end of 2001."
VANLEV was compared in the OCTAVE study to enalapril, one of the widely-used class of antihypertensive drugs known as ACE inhibitors. The company also noted that its separate clinical study known as OVERTURE**, which is investigating VANLEV in the treatment of congestive heart failure, is expected to be completed early next year.
The company earlier reported that, pending supportive results from the OCTAVE study, it expected to make a decision to re-file its NDA

in the September/October timeframe. To preserve the integrity of the NDA review, the company said it does not intend to publicly disclose OCTAVE data until the FDA has completed is review process of the NDA submission.
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that may be identified by terminology such as "expects" and other words or terms of similar expression or meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, uncertainties relating to product development, unexpected regulatory delays and government regulation generally. For further details and a discussion of these and other risks and uncertainties, see the company's Securities Exchange and Commission fillings, including the company's 2000 annual report on Form 10K. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
# # #
*OCTAVE (Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril)
**OVERTURE (Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events)